Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro
© 2022 Wiley Periodicals LLC..
The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with the most contagious variants, alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2), and Omicron (B.1.1.529) has continuously added a higher number of morbidity and mortality, globally. The present integrated bioinformatics-cheminformatics approach was employed to locate potent antiviral marine alkaloids that could be used against SARS-CoV-2. Initially, 57 antiviral marine alkaloids and two repurposing drugs were selected from an extensive literature review. Then, the putative target enzyme SARS-CoV-2 main protease (SARS-CoV-2-Mpro) was retrieved from the protein data bank and carried out a virtual screening-cum-molecular docking study with all candidates using PyRx 0.8 and AutoDock 4.2 software. Further, the molecular dynamics (MD) simulation of the two most potential alkaloids and a drug docking complex at 100 ns (with two ligand topology files from PRODRG and ATB server, separately), the molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) free energy, and contributions of entropy were investigated. Then, the physicochemical-toxicity-pharmacokinetics-drug-likeness profiles, the frontier molecular orbitals energies (highest occupied molecular orbital, lowest unoccupied molecular orbital, and ΔE), and structural-activity relationship were assessed and analyzed. Based on binding energy, 8-hydroxymanzamine (-10.5 kcal/mol) and manzamine A (-10.1 kcal/mol) from all alkaloids with darunavir (-7.9 kcal/mol) and lopinavir (-7.4 kcal/mol) against SARS-CoV-2-Mpro were recorded. The MD simulation (RMSD, RMSF, Rg, H-bond, MM/PBSA binding energy) illustrated that the 8-hydroxymanzamine exhibits a static thermodynamic feature than the other two complexes. The predicted physicochemical, toxicity, pharmacokinetics, and drug-likeness profiles also revealed that the 8-hydroxymanzamine could be used as a potential lead candidate individually and/or synergistically with darunavir or lopinavir to combat SARS-CoV-2 infection after some pharmacological validation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
---|---|
Enthalten in: |
Proteins - 90(2022), 9 vom: 20. Sept., Seite 1617-1633 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Swain, Shasank S [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 09.08.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/prot.26341 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM339138238 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM339138238 | ||
003 | DE-627 | ||
005 | 20231226002232.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/prot.26341 |2 doi | |
028 | 5 | 2 | |a pubmed24n1130.xml |
035 | |a (DE-627)NLM339138238 | ||
035 | |a (NLM)35384056 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Swain, Shasank S |e verfasserin |4 aut | |
245 | 1 | 0 | |a Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.08.2022 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022 Wiley Periodicals LLC. | ||
520 | |a The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with the most contagious variants, alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2), and Omicron (B.1.1.529) has continuously added a higher number of morbidity and mortality, globally. The present integrated bioinformatics-cheminformatics approach was employed to locate potent antiviral marine alkaloids that could be used against SARS-CoV-2. Initially, 57 antiviral marine alkaloids and two repurposing drugs were selected from an extensive literature review. Then, the putative target enzyme SARS-CoV-2 main protease (SARS-CoV-2-Mpro) was retrieved from the protein data bank and carried out a virtual screening-cum-molecular docking study with all candidates using PyRx 0.8 and AutoDock 4.2 software. Further, the molecular dynamics (MD) simulation of the two most potential alkaloids and a drug docking complex at 100 ns (with two ligand topology files from PRODRG and ATB server, separately), the molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) free energy, and contributions of entropy were investigated. Then, the physicochemical-toxicity-pharmacokinetics-drug-likeness profiles, the frontier molecular orbitals energies (highest occupied molecular orbital, lowest unoccupied molecular orbital, and ΔE), and structural-activity relationship were assessed and analyzed. Based on binding energy, 8-hydroxymanzamine (-10.5 kcal/mol) and manzamine A (-10.1 kcal/mol) from all alkaloids with darunavir (-7.9 kcal/mol) and lopinavir (-7.4 kcal/mol) against SARS-CoV-2-Mpro were recorded. The MD simulation (RMSD, RMSF, Rg, H-bond, MM/PBSA binding energy) illustrated that the 8-hydroxymanzamine exhibits a static thermodynamic feature than the other two complexes. The predicted physicochemical, toxicity, pharmacokinetics, and drug-likeness profiles also revealed that the 8-hydroxymanzamine could be used as a potential lead candidate individually and/or synergistically with darunavir or lopinavir to combat SARS-CoV-2 infection after some pharmacological validation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a antiviral marine alkaloids | |
650 | 4 | |a drug-likeness profiles prediction | |
650 | 4 | |a molecular docking simulation | |
650 | 4 | |a severe acute respiratory syndrome coronavirus-2-Mpro | |
650 | 7 | |a Alkaloids |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Protease Inhibitors |2 NLM | |
650 | 7 | |a Lopinavir |2 NLM | |
650 | 7 | |a 2494G1JF75 |2 NLM | |
650 | 7 | |a 3C-like proteinase, SARS-CoV-2 |2 NLM | |
650 | 7 | |a EC 3.4.22.- |2 NLM | |
650 | 7 | |a Cysteine Endopeptidases |2 NLM | |
650 | 7 | |a EC 3.4.22.- |2 NLM | |
650 | 7 | |a Coronavirus 3C Proteases |2 NLM | |
650 | 7 | |a EC 3.4.22.28 |2 NLM | |
650 | 7 | |a Darunavir |2 NLM | |
650 | 7 | |a YO603Y8113 |2 NLM | |
700 | 1 | |a Singh, Satya R |e verfasserin |4 aut | |
700 | 1 | |a Sahoo, Alaka |e verfasserin |4 aut | |
700 | 1 | |a Panda, Pritam Kumar |e verfasserin |4 aut | |
700 | 1 | |a Hussain, Tahziba |e verfasserin |4 aut | |
700 | 1 | |a Pati, Sanghamitra |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Proteins |d 1988 |g 90(2022), 9 vom: 20. Sept., Seite 1617-1633 |w (DE-627)NLM012942030 |x 1097-0134 |7 nnns |
773 | 1 | 8 | |g volume:90 |g year:2022 |g number:9 |g day:20 |g month:09 |g pages:1617-1633 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/prot.26341 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 90 |j 2022 |e 9 |b 20 |c 09 |h 1617-1633 |